The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
At the center of the collapse is opposition from the Federal Trade Commission
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
The initial consideration for the transaction is US$ 12 million
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
SPARK has extended its influence to an additional 9.47 million students worldwide
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
Subscribe To Our Newsletter & Stay Updated
